Morepen Laboratories

Morepen Laboratories shares jumped 5.7 per cent, after the company arm Morepen Medipath executed a joint venture (JV) agreement with Bimedical FZE, a UAE based entity

Morepen Laboratories on Friday said it will add more than 1,000 medical representatives over the next three years, with over 200 team members expected to join in FY26 alone. The company aims to strengthen its formulations business in the market through new hirings. "This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domestic finished dosage market," Morepen Laboratories Chairman and MD Sushil Suri said in a statement. With significant increase in the sales force and enhanced reach to doctors, pharmacies, and patients, the drugmaker is setting the stage for getting a bigger pie in the Indian pharmaceutical market valued at Rs 2.38 lakh crore, yielding higher gross margins and better returns for stakeholders in the long run, he added. Currently, Morepen's formulation business stands around Rs 325 crore, and the company is targeting to touch Rs 1,000 crore in the next five years. This goal will be supported by an aggressive expans

The uptick in the Morepen Labs share came after the company announced that it has rolled out 'Empamore.'

Morepen Labs share price: Volumes on the Morepen Labs counter jumped suddenly around 1:05 PM with around 1.67 million shares changing hands in multiple tranches on the BSE

Company eyes Rs 30 crore revenue in first year, Rs 200 crore by 2030

Expanding capacities, backward integrating production and eyeing US market for exports

Earlier this month, the company had incorporated a wholly-owned subsidiary, Morepen RX.

Drug firm Morepen Laboratories on Thursday said its consolidated net profit declined by 55 per cent to Rs 12 crore for the fourth quarter ended March 2022.

Morepen's product is the generic version of Sanofi Aventis' anti- allergy drug.

Morepen Laboratories on Wednesday said its shareholders have approved to shift its medical devices business into a newly incorporated wholly-owned subsidiary

The approval of samples, licensing, and final production will take around two months and the vaccine would be available in India for sale also in two months, says CMD Sushil Suri

Drug firm Morepen Laboratories on Tuesday reported an over two-fold rise in its consolidated net profit at Rs 26.76 crore for the quarter ended March 31, 2021, on account of higher revenue

On April 28, Morepen Group sealed $100 million (Rs 750 crore approx.) investment from Corinth Group of Switzerland

Morepen Laboratories said its board has approved raising over Rs 433 crore through issue of shares to Switzerland's private venture capital firm Corinth Investment Holdings and Liquid Holdings

Morepen Laboratories was locked in upper circuit for the third straight trading day, up 10% at Rs 19.43 on the BSE.

In a clarification issued today, the company said that the matter was pertaining to the year 2003 which has been finally settled by the Sebi.

The stock surged 14% to Rs 36.20 on the NSE after the company received USFDA approval for both its bulk drugs manufacturing facilities situated in Himachal Pradesh.

The stock surged 18% to Rs 29.60, also its 52-week high on NSE, after the pharmaceutical company announced that the USFDA has cleared anti-asthmatic drug, Montelukast Sodium.

The stock hit a high of Rs 27.25 and a low of Rs 26.10 so far during the day

To expand its services in the diagnostics and therapy segment in the coming years